دورية أكاديمية
أعرض في EDS

Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review.

التفاصيل البيبلوغرافية
العنوان: Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review.
المؤلفون: Ogiji ED; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.; Department of Pharmacology and Therapeutics, Ebonyi State University, Abakaliki, Nigeria., Aboheimed N; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.; Department of Pharmacy Practice, Princess Nourah bint Abdulrahman University, Saudi Arabia., Ross K; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University., Voller C; School of Medicine, University of Liverpool, Liverpool, UK., Siner R; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Jensen RL; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Jolly CE; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK., Carr DF; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
المصدر: Current opinion in allergy and clinical immunology [Curr Opin Allergy Clin Immunol] 2024 Aug 01; Vol. 24 (4), pp. 218-227. Date of Electronic Publication: 2024 May 17.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 100936359 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-6322 (Electronic) Linking ISSN: 14736322 NLM ISO Abbreviation: Curr Opin Allergy Clin Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md. : Lippincott Williams & Wilkins, c2001-
مواضيع طبية MeSH: Stevens-Johnson Syndrome*/immunology , Stevens-Johnson Syndrome*/therapy , Stevens-Johnson Syndrome*/pathology , Stevens-Johnson Syndrome*/etiology, Humans ; Immunoglobulins, Intravenous/therapeutic use ; Skin/pathology ; Skin/immunology ; Skin/drug effects ; Adrenal Cortex Hormones/therapeutic use ; Animals ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/adverse effects
مستخلص: Purpose of Review: Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) are severe cutaneous adverse drug reactions (SCARs) characterized by widespread epithelial detachment and blistering, which affects the skin and mucocutaneous membranes. To date, therapeutic interventions for SJS/TEN have focused on systematic suppression of the inflammatory response using high-dose corticosteroids or intravenous immunoglobulin G (IgG), for example. No targeted therapies for SJS/TEN currently exist.
Recent Findings: Though our understanding of the pathogenesis of SJS/TEN has advanced from both an immunological and dermatological perspective, this knowledge is yet to translate into the development of new targeted therapies.
Summary: Greater mechanistic insight into SJS/TEN would potentially unlock new opportunities for identifying or repurposing targeted therapies to limit or even prevent epidermal injury and blistering.
(Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
References: Arch Dermatol. 2011 Sep;147(9):1110-2. (PMID: 21931056)
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):38-69. (PMID: 29310768)
J Immunol. 2008 Dec 15;181(12):8576-84. (PMID: 19050277)
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):367-375. (PMID: 30357932)
Neurol Neuroimmunol Neuroinflamm. 2023 Apr 20;10(4):. (PMID: 37080596)
N Engl J Med. 2012 Mar 29;366(13):1181-9. (PMID: 22455412)
J Intern Med. 2014 Nov;276(5):420-4. (PMID: 25346011)
Drug Saf. 2019 Aug;42(8):973-992. (PMID: 31020549)
Cochrane Database Syst Rev. 2022 Mar 11;3:CD013130. (PMID: 35274741)
J Invest Dermatol. 2003 Jan;120(1):164-7. (PMID: 12535213)
Int Immunol. 2008 Aug;20(8):1019-30. (PMID: 18550585)
Oral Oncol. 2022 Sep;132:106008. (PMID: 35803110)
J Clin Invest. 2002 Oct;110(7):983-92. (PMID: 12370276)
J Pharm Sci. 2020 Oct;109(10):3134-3144. (PMID: 32621836)
J Allergy Clin Immunol. 2004 Aug;114(2):335-40. (PMID: 15316512)
J Am Acad Dermatol. 2008 Jan;58(1):25-32. (PMID: 17919772)
Arch Dermatol Res. 1997 Aug;289(9):527-32. (PMID: 9341973)
J Cell Immunol. 2019;1(2):33-42. (PMID: 31984378)
Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):141-8. (PMID: 20123076)
Mol Cancer Ther. 2015 Nov;14(11):2665-73. (PMID: 26330548)
Br J Dermatol. 2006 Oct;155(4):722-8. (PMID: 16965421)
J Inflamm Res. 2018 Mar 28;11:135-142. (PMID: 29636627)
Dermatol Ther (Heidelb). 2023 Jun;13(6):1305-1327. (PMID: 37178320)
J Plast Reconstr Aesthet Surg. 2016 Jun;69(6):e119-e153. (PMID: 27287213)
Psoriasis (Auckl). 2019 Feb 12;9:7-17. (PMID: 30859087)
J Antimicrob Chemother. 2006 Feb;57(2):260-5. (PMID: 16387752)
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):296-301. (PMID: 14695889)
J Invest Dermatol. 2023 Jun;143(6):1023-1030.e7. (PMID: 36581093)
Nat Med. 2008 Dec;14(12):1343-50. (PMID: 19029983)
J Immunotoxicol. 2021 Dec;18(1):74-84. (PMID: 34019775)
J Burn Care Res. 2007 Sep-Oct;28(5):669-74. (PMID: 17969245)
Clin Exp Dermatol. 2017 Dec;42(8):868-873. (PMID: 28940568)
Periodontol 2000. 2015 Oct;69(1):142-59. (PMID: 26252407)
PLoS One. 2009;4(5):e5263. (PMID: 19421322)
Bioorg Med Chem Lett. 2016 Nov 1;26(21):5277-5283. (PMID: 27692854)
Front Pharmacol. 2021 Apr 26;12:588063. (PMID: 33981213)
J Allergy Clin Immunol. 2013 Feb;131(2):434-41.e1-9. (PMID: 23111236)
JAMA Dermatol. 2023 Apr 1;159(4):384-392. (PMID: 36790777)
J Interferon Cytokine Res. 2011 Feb;31(2):249-57. (PMID: 21087077)
Diabetes. 2018 Aug;67(8):1627-1638. (PMID: 29748291)
Nutrients. 2020 Oct 24;12(11):. (PMID: 33114438)
J Allergy Clin Immunol Pract. 2019 Jan;7(1):325-327. (PMID: 29936189)
N Engl J Med. 2016 Dec 15;375(24):2335-2348. (PMID: 27690741)
Bioengineering (Basel). 2021 Oct 20;8(11):. (PMID: 34821714)
Annu Rev Biomed Eng. 2017 Jun 21;19:1-26. (PMID: 28226217)
J Am Acad Dermatol. 2002 Jul;47(1):58-62. (PMID: 12077582)
Ann Allergy Asthma Immunol. 2006 Sep;97(3):272-80; quiz 281-3, 320. (PMID: 17042130)
Skinmed. 2023 Mar 29;21(1):40-43. (PMID: 36987827)
Clin Exp Allergy. 2013 Sep;43(9):1027-37. (PMID: 23957338)
J Leukoc Biol. 2013 Jun;93(6):865-73. (PMID: 23446148)
N Engl J Med. 1995 Dec 14;333(24):1600-7. (PMID: 7477195)
PLoS One. 2017 Aug 24;12(8):e0183542. (PMID: 28837619)
Toxicology. 2005 Apr 15;209(2):123-9. (PMID: 15767024)
Nat Med. 2002 Feb;8(2):157-65. (PMID: 11821900)
Front Med (Lausanne). 2023 Apr 18;10:1165098. (PMID: 37144036)
Biomedicines. 2022 Aug 02;10(8):. (PMID: 36009415)
Burns. 2016 Jun;42(4):830-5. (PMID: 26810444)
J Invest Dermatol. 2017 Jun;137(6):1240-1247. (PMID: 28202399)
Exp Biol Med (Maywood). 2017 Jun;242(11):1158-1169. (PMID: 28585891)
Front Immunol. 2021 Jan 29;11:578129. (PMID: 33584645)
J Am Acad Dermatol. 2011 Jul;65(1):65-8. (PMID: 21507517)
Sci Transl Med. 2014 Feb 12;6(223):223ra23. (PMID: 24523323)
Dermatol Ther. 2019 Jul;32(4):e12832. (PMID: 30659711)
Dermatol Ther (Heidelb). 2023 Mar;13(3):729-749. (PMID: 36790724)
Dermatology. 2007;214(4):296-304. (PMID: 17460400)
Pharmaceutics. 2012 Jan 06;4(1):26-41. (PMID: 24300178)
Asian Pac J Allergy Immunol. 2016 Sep;34(3):236-241. (PMID: 27001652)
Br J Dermatol. 2008 Jan;158(1):184-6. (PMID: 17941938)
J Invest Dermatol. 2017 Nov;137(11):2371-2379. (PMID: 28647349)
JAMA Dermatol. 2020 Apr 1;156(4):411-420. (PMID: 32101256)
Front Bioeng Biotechnol. 2021 Nov 26;9:778269. (PMID: 34900966)
Int J Mol Sci. 2019 Apr 03;20(7):. (PMID: 30987186)
Sci Transl Med. 2021 Jun 30;13(600):. (PMID: 34193610)
J Exp Med. 2000 Mar 6;191(5):771-80. (PMID: 10704459)
N Engl J Med. 2019 Sep 26;381(13):1201-1214. (PMID: 31553833)
J Viral Hepat. 2014 Feb;21(2):129-40. (PMID: 24383926)
Clin Transl Allergy. 2018 Apr 20;8:12. (PMID: 29713456)
J Clin Invest. 2018 Mar 1;128(3):985-996. (PMID: 29400697)
Phytother Res. 2010 Jun;24(6):905-12. (PMID: 19943332)
Case Rep Dermatol. 2022 Jul 14;14(2):203-209. (PMID: 36158858)
BMC Rheumatol. 2022 Sep 27;6(1):71. (PMID: 36163193)
J Dermatol. 2023 Sep;50(9):1129-1139. (PMID: 37269158)
J Invest Dermatol. 2017 May;137(5):1065-1073. (PMID: 28011147)
Mol Med. 2015 Jan 27;20:538-47. (PMID: 25247290)
J Atheroscler Thromb. 2016 Jun 1;23(6):737-45. (PMID: 26830200)
J Allergy Clin Immunol. 2002 Jan;109(1):155-61. (PMID: 11799383)
Indian J Dermatol Venereol Leprol. 2016 Nov-Dec;82(6):603-625. (PMID: 27716721)
Arch Dermatol Res. 2004 Oct;296(5):220-5. (PMID: 15449075)
Br J Dermatol. 2014 Dec;171(6):1585-8. (PMID: 24903194)
J Allergy Clin Immunol. 2008 Nov;122(5):992-1000. (PMID: 18692887)
J Immunol. 2009 Jul 1;183(1):543-51. (PMID: 19542465)
Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8705-9. (PMID: 7568001)
JAMA Dermatol. 2023 May 1;159(5):481-487. (PMID: 36884227)
Arch Dermatol. 1997 Jul;133(7):845-9. (PMID: 9236522)
J Invest Dermatol. 1997 Sep;109(3):334-9. (PMID: 9284101)
J Am Acad Dermatol. 2020 Jun;82(6):1553-1567. (PMID: 32151629)
Mol Med. 2010 Sep-Oct;16(9-10):343-51. (PMID: 20386869)
Epilepsia. 2018 Dec;59(12):2318-2324. (PMID: 30395352)
Pediatr Dermatol. 2018 Sep;35(5):616-621. (PMID: 29999197)
Nature. 1995 Oct 5;377(6548):446-8. (PMID: 7566124)
Sci Transl Med. 2014 Jul 16;6(245):245ra95. (PMID: 25031270)
Chem Res Toxicol. 2015 May 18;28(5):927-34. (PMID: 25811541)
N Engl J Med. 2014 Jul 24;371(4):326-38. (PMID: 25007392)
EMBO J. 1990 Aug;9(8):2529-36. (PMID: 2369902)
Mol Divers. 2022 Oct;26(5):2659-2678. (PMID: 35031934)
Blood. 2013 Jan 17;121(3):476-84. (PMID: 23212516)
Chem Biol. 2007 Apr;14(4):431-41. (PMID: 17462578)
Nat Rev Nephrol. 2016 Jul;12(7):402-13. (PMID: 27241241)
Acta Derm Venereol. 2007;87(2):144-8. (PMID: 17340021)
J Hematol Oncol. 2020 Aug 24;13(1):116. (PMID: 32831115)
Br J Dermatol. 2010 May;162(5):1014-22. (PMID: 20030638)
N Engl J Med. 2021 Jul 8;385(2):130-141. (PMID: 33891379)
J Exp Med. 2012 Mar 12;209(3):551-63. (PMID: 22370717)
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620950831. (PMID: 33560872)
Br J Dermatol. 2019 Jul;181(1):166-174. (PMID: 30613954)
J Am Acad Dermatol. 2022 Jun;86(6):1236-1245. (PMID: 35121075)
J Exp Med. 2015 Jan 12;212(1):5-14. (PMID: 25559892)
Allergy. 2023 May;78(5):1280-1291. (PMID: 36463488)
المشرفين على المادة: 0 (Immunoglobulins, Intravenous)
0 (Adrenal Cortex Hormones)
تواريخ الأحداث: Date Created: 20240516 Date Completed: 20240627 Latest Revision: 20240630
رمز التحديث: 20240630
مُعرف محوري في PubMed: PMC11213502
DOI: 10.1097/ACI.0000000000000993
PMID: 38753537
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-6322
DOI:10.1097/ACI.0000000000000993